0 Bewertungen

ID

17916

Beschreibung

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00065325

Link

https://clinicaltrials.gov/show/NCT00065325

Stichworte

  1. 09.10.16 09.10.16 -
Hochgeladen am

9. Oktober 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :


    Keine Kommentare

    Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

    Eligibility Locally Advanced Breast Cancer NCT00065325

    Eligibility Locally Advanced Breast Cancer NCT00065325

    Inclusion Criteria
    Beschreibung

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    biopsy confirmation of breast cancer
    Beschreibung

    Breast Carcinoma | Biopsy

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0678222
    UMLS CUI [2]
    C0005558
    breast cancer has continued to grow after having received treatment with an aromatase inhibitor
    Beschreibung

    Therapeutic procedure Breast Carcinoma | Aromatase Inhibitor | Disease Progression

    Datentyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0087111
    UMLS CUI [1,2]
    C0678222
    UMLS CUI [2]
    C0593802
    UMLS CUI [3]
    C0242656
    postmenopausal women defined as a women who has stopped having menstrual periods
    Beschreibung

    Postmenopausal state | Periods have stopped

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0232970
    UMLS CUI [2]
    C0425957
    evidence of hormone sensitivity
    Beschreibung

    hormone sensitivity Evidence of

    Datentyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0920555
    UMLS CUI [1,2]
    C0332120
    written informed consent to participate in the trial
    Beschreibung

    Informed Consent

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0021430
    Exclusion Criteria
    Beschreibung

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    previous treatment with faslodex (fulvestrant) or aromasin (exemestane)
    Beschreibung

    Faslodex | fulvestrant | Aromasin | exemestane

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0701491
    UMLS CUI [2]
    C0935916
    UMLS CUI [3]
    C0876723
    UMLS CUI [4]
    C0851344
    any hormonal therapy used to modify the course of an additional medical condition after prior treatment with a non-steroidal aromatase inhibitor
    Beschreibung

    Hormone Therapy Other medical condition Changing | Non-Steroidal Aromatase Inhibitor

    Datentyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0279025
    UMLS CUI [1,2]
    C3843040
    UMLS CUI [1,3]
    C0392747
    UMLS CUI [2]
    C1518386
    treatment with an investigational or non-approved drug within one month
    Beschreibung

    Investigational New Drugs | Illicit Drugs

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0013230
    UMLS CUI [2]
    C0086190
    an existing serious disease, illness, or condition that will prevent participation or compliance with study procedures
    Beschreibung

    Disease Serious Preventing participation | Disease Serious Preventing Protocol Compliance | Condition Preventing participation | Condition Preventing Protocol Compliance

    Datentyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0012634
    UMLS CUI [1,2]
    C0205404
    UMLS CUI [1,3]
    C1292733
    UMLS CUI [1,4]
    C0679823
    UMLS CUI [2,1]
    C0012634
    UMLS CUI [2,2]
    C0205404
    UMLS CUI [2,3]
    C1292733
    UMLS CUI [2,4]
    C0525058
    UMLS CUI [3,1]
    C0348080
    UMLS CUI [3,2]
    C1292733
    UMLS CUI [3,3]
    C0679823
    UMLS CUI [4,1]
    C0348080
    UMLS CUI [4,2]
    C1292733
    UMLS CUI [4,3]
    C0525058
    a history of allergies to any active or inactive ingredients of faslodex or exemestane (i.e. castor oil or mannitol)
    Beschreibung

    Hypersensitivity Faslodex Ingredient | Hypersensitivity exemestane Ingredient | Hypersensitivity Castor Oil | Hypersensitivity Mannitol

    Datentyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0020517
    UMLS CUI [1,2]
    C0701491
    UMLS CUI [1,3]
    C1550600
    UMLS CUI [2,1]
    C0020517
    UMLS CUI [2,2]
    C0851344
    UMLS CUI [2,3]
    C1550600
    UMLS CUI [3,1]
    C0020517
    UMLS CUI [3,2]
    C0007343
    UMLS CUI [4,1]
    C0020517
    UMLS CUI [4,2]
    C0024730

    Ähnliche Modelle

    Eligibility Locally Advanced Breast Cancer NCT00065325

    Name
    Typ
    Description | Question | Decode (Coded Value)
    Datentyp
    Alias
    Item Group
    C1512693 (UMLS CUI)
    Breast Carcinoma | Biopsy
    Item
    biopsy confirmation of breast cancer
    boolean
    C0678222 (UMLS CUI [1])
    C0005558 (UMLS CUI [2])
    Therapeutic procedure Breast Carcinoma | Aromatase Inhibitor | Disease Progression
    Item
    breast cancer has continued to grow after having received treatment with an aromatase inhibitor
    boolean
    C0087111 (UMLS CUI [1,1])
    C0678222 (UMLS CUI [1,2])
    C0593802 (UMLS CUI [2])
    C0242656 (UMLS CUI [3])
    Postmenopausal state | Periods have stopped
    Item
    postmenopausal women defined as a women who has stopped having menstrual periods
    boolean
    C0232970 (UMLS CUI [1])
    C0425957 (UMLS CUI [2])
    hormone sensitivity Evidence of
    Item
    evidence of hormone sensitivity
    boolean
    C0920555 (UMLS CUI [1,1])
    C0332120 (UMLS CUI [1,2])
    Informed Consent
    Item
    written informed consent to participate in the trial
    boolean
    C0021430 (UMLS CUI [1])
    Item Group
    C0680251 (UMLS CUI)
    Faslodex | fulvestrant | Aromasin | exemestane
    Item
    previous treatment with faslodex (fulvestrant) or aromasin (exemestane)
    boolean
    C0701491 (UMLS CUI [1])
    C0935916 (UMLS CUI [2])
    C0876723 (UMLS CUI [3])
    C0851344 (UMLS CUI [4])
    Hormone Therapy Other medical condition Changing | Non-Steroidal Aromatase Inhibitor
    Item
    any hormonal therapy used to modify the course of an additional medical condition after prior treatment with a non-steroidal aromatase inhibitor
    boolean
    C0279025 (UMLS CUI [1,1])
    C3843040 (UMLS CUI [1,2])
    C0392747 (UMLS CUI [1,3])
    C1518386 (UMLS CUI [2])
    Investigational New Drugs | Illicit Drugs
    Item
    treatment with an investigational or non-approved drug within one month
    boolean
    C0013230 (UMLS CUI [1])
    C0086190 (UMLS CUI [2])
    Disease Serious Preventing participation | Disease Serious Preventing Protocol Compliance | Condition Preventing participation | Condition Preventing Protocol Compliance
    Item
    an existing serious disease, illness, or condition that will prevent participation or compliance with study procedures
    boolean
    C0012634 (UMLS CUI [1,1])
    C0205404 (UMLS CUI [1,2])
    C1292733 (UMLS CUI [1,3])
    C0679823 (UMLS CUI [1,4])
    C0012634 (UMLS CUI [2,1])
    C0205404 (UMLS CUI [2,2])
    C1292733 (UMLS CUI [2,3])
    C0525058 (UMLS CUI [2,4])
    C0348080 (UMLS CUI [3,1])
    C1292733 (UMLS CUI [3,2])
    C0679823 (UMLS CUI [3,3])
    C0348080 (UMLS CUI [4,1])
    C1292733 (UMLS CUI [4,2])
    C0525058 (UMLS CUI [4,3])
    Hypersensitivity Faslodex Ingredient | Hypersensitivity exemestane Ingredient | Hypersensitivity Castor Oil | Hypersensitivity Mannitol
    Item
    a history of allergies to any active or inactive ingredients of faslodex or exemestane (i.e. castor oil or mannitol)
    boolean
    C0020517 (UMLS CUI [1,1])
    C0701491 (UMLS CUI [1,2])
    C1550600 (UMLS CUI [1,3])
    C0020517 (UMLS CUI [2,1])
    C0851344 (UMLS CUI [2,2])
    C1550600 (UMLS CUI [2,3])
    C0020517 (UMLS CUI [3,1])
    C0007343 (UMLS CUI [3,2])
    C0020517 (UMLS CUI [4,1])
    C0024730 (UMLS CUI [4,2])

    Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

    Zum Video